应用UGRP1预测Graves病患者碘131治疗发生甲减风险

Application of UGRP1 to predict the risk of hypothyroidism in patients with Graves’ disease treated with iodine-131

目的探讨格雷夫斯病(GD)患者甲状腺细胞子宫球蛋白相关蛋白1(UGRP1)的表达与碘131(131I)治疗后甲状腺功能减退症(甲减)发生风险之间的关系。方法38例拟行131I治疗的GD患者,通过免疫组化方法检测甲状腺穿刺细胞学所取甲状腺细胞UGRP1的表达,分为UGRP1阳性组(20例)和UGRP1阴性组(18例),131I治疗后12周随访甲状腺功能,分别计算两组的甲减发生率。结果UGRP1阳性组采用131I治疗,甲减发生率75%;UGRP1阴性组采用131I治疗,甲减发生率33%,两组比较差异有统计学意义(P<0.01)。结论UGRP1阳性表达组采用131I治疗甲减发生风险较阴性表达组高,提示可以根据UGRP1的表达情况预测GD患者131I治疗发生甲减风险。

Objective To study the relationship between the expression of UGRP1 in thyroid cells of patients with Graves' disease and the probability of hypothyroidism after iodine-131 treatment. Methods Immunohistochemical method was used to detect the expression of UGRP1 in thyroid cells of 38 patients with Graves' disease by fine needle aspiration biopsy (FNAB) prior to the treatment of iodine-131.The thyroid was followed up 12 weeks after iodine-131 treatment.The incidences of hypothyroidism in the UGRP1-positive group of thyroid cells and the UGRP1-negative group were calculated respectively. Results After treated with iodine-131,the incidence of hypothyroidism in the UGRP1-positive expression group was 75%,and the UGRP1-negative expression group was 33%.There was significant difference between the two groups ( P <0.01). Conclusion The incidence of hypothyroidism in UGRP1-positive expression group is higher than that in negative expression group,which suggests that the positive expression of UGRP1 in thyroid cells can be used to predict the risk of hypothyroidism in patients of Graves' disease treated with iodine-131.